NASDAQ:VRPX Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free VRPX Stock Alerts $2.92 -0.25 (-7.89%) (As of 05:13 PM ET) Add Compare Share Share Today's Range$2.85▼$3.0650-Day Range$2.70▼$4.9552-Week Range$2.40▼$11.77Volume8,337 shsAverage Volume20,382 shsMarket Capitalization$3.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Virpax Pharmaceuticals alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Virpax Pharmaceuticals Stock (NASDAQ:VRPX)Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.Read More VRPX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRPX Stock News HeadlinesApril 24, 2024 | investorplace.comVRPX Stock Earnings: Virpax Pharmaceuticals Misses EPS for Q4 2023April 2, 2024 | msn.comVirpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management SolutionsApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.March 26, 2024 | businesswire.comVirpax Pharmaceuticals Reports 2023 Year-End ResultsFebruary 27, 2024 | finance.yahoo.comVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid PriceFebruary 27, 2024 | businesswire.comVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid PriceFebruary 27, 2024 | businesswire.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 12, 2024 | msn.comVirpax Pharmaceuticals Reports Promising Results in Probudur Pilot StudyApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.February 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)February 7, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and EyePoint Pharmaceuticals (EYPT)January 23, 2024 | investing.comVirpax Pharmaceuticals Inc (VRPX)December 29, 2023 | msn.comVirpax Pharmaceuticals shareholders okay reverse stock splitDecember 28, 2023 | msn.comTitan Pharmaceuticals to conduct 1-for-20 reverse stock splitNovember 22, 2023 | seekingalpha.comVRPX Virpax Pharmaceuticals, Inc.November 18, 2023 | markets.businessinsider.comPromising Pipeline Developments and Market Opportunities Drive Buy Rating for Virpax PharmaceuticalsNovember 17, 2023 | msn.comVirpax Pharmaceuticals gets non-compliance notice from NasdaqNovember 17, 2023 | msn.comVirpax Pharmaceuticals CEO and Chairman resigns on ongoing litigationNovember 17, 2023 | finance.yahoo.comVirpax Pharmaceuticals Announces Leadership TransitionNovember 17, 2023 | finance.yahoo.comVirpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q FilingNovember 15, 2023 | msn.comVirpax Pharmaceuticals GAAP EPS of -$0.51October 31, 2023 | finance.yahoo.comVirpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA ReviewSeptember 28, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Virpax Pharmaceuticals (VRPX), Kura Oncology (KURA)September 27, 2023 | finance.yahoo.comVirpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation StudiesSeptember 26, 2023 | finance.yahoo.comVirpax Pharmaceuticals to Present at the LD Micro Main Event XVISeptember 21, 2023 | businesswire.comAltasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like VirusesSeptember 18, 2023 | finance.yahoo.comVirpax Pharmaceuticals Announces the Formation of Novvae™ PharmaceuticalsSee More Headlines Receive VRPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virpax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VRPX CUSIPN/A CIK1708331 Webwww.virpaxpharma.com Phone610-727-4597FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($11.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-169.04% Return on Assets-106.39% Debt Debt-to-Equity RatioN/A Current Ratio1.25 Quick Ratio1.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.65 per share Price / Book1.81Miscellaneous Outstanding Shares1,170,000Free Float1,098,000Market Cap$3.49 million OptionableNot Optionable Beta1.38 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Gerald W. Bruce (Age 67)CEO & Director Comp: $371.87kDr. Sheila A. Mathias J.D. (Age 56)M.B.A., Ph.D., Chief Scientific Officer Comp: $698.97kDr. Jeffrey A. Gudin M.D. (Age 58)Executive VP, Chief Medical Officer & Director Comp: $158kMr. Vinay Shah A.C.A. (Age 61)M.B.A., CFO, Principal Financial Officer, Principal Accounting Officer & Corporate Secretary Ms. Shana PanzarellaChief of StaffKey CompetitorsMustang BioNASDAQ:MBIOEvoke PharmaNASDAQ:EVOKGeoVax LabsNASDAQ:GOVXPhaseBio PharmaceuticalsNASDAQ:PHASRevelation BiosciencesNASDAQ:REVBView All Competitors VRPX Stock Analysis - Frequently Asked Questions How have VRPX shares performed in 2024? Virpax Pharmaceuticals' stock was trading at $3.2010 on January 1st, 2024. Since then, VRPX shares have decreased by 6.9% and is now trading at $2.98. View the best growth stocks for 2024 here. Are investors shorting Virpax Pharmaceuticals? Virpax Pharmaceuticals saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 14,800 shares, a decrease of 50.3% from the March 31st total of 29,800 shares. Based on an average daily volume of 23,800 shares, the short-interest ratio is presently 0.6 days. Approximately 1.7% of the company's stock are sold short. View Virpax Pharmaceuticals' Short Interest. When is Virpax Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our VRPX earnings forecast. When did Virpax Pharmaceuticals' stock split? Virpax Pharmaceuticals's stock reverse split on the morning of Friday, March 1st 2024. The 1-10 reverse split was announced on Friday, March 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Virpax Pharmaceuticals IPO? Virpax Pharmaceuticals (VRPX) raised $15 million in an IPO on Wednesday, February 17th 2021. The company issued 1,400,000 shares at $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. How do I buy shares of Virpax Pharmaceuticals? Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VRPX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe World's First "$20 Trillion Drug?"Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
